MDSpire - Summary
From the Journals

Tirzepatide Linked to Greater QoL Gains vs Dulaglutide

Both groups improved, with numerically larger gains in patient-reported outcomes following a switch to tirzepatide

Share

The SURPASS-SWITCH trial indicates that switching from dulaglutide to tirzepatide results in greater enhancements in patient-reported outcomes, such as emotional health and quality of life, for adults with type 2 diabetes inadequately controlled on stable dulaglutide therapy. The 40-week phase 4 trial assessed the impact of both treatment strategies on various validated measures. Observations revealed that those switching to tirzepatide experienced superior improvements in emotional well-being and daily functioning, reinforcing its potential benefits beyond glycemic control.

Original Source(s)

Tirzepatide Linked to Greater QoL Gains vs Dulaglutide

  • by Conexiant News Staff

  • March 30, 2026

Related Content

Fluvoxamine Reduces Long COVID Fatigue in Trial

A randomized, placebo-controlled trial found the selective serotonin reuptake inhibitor improved fatigue severity vs placebo, while metformin showed no evidence of benefit.

Inside Access, Outside the Rules

Two federal cases highlight alleged misuse of professional roles in health care settings

Side Effects: Variety Is Overrated

The organ you forgot, the cells that age unevenly, the AI that admits ignorance, and the diet advice that sounds wrong but isn't: medicine's next moves are hiding in plain sight.